Higuchi John W. purchased $225K of LPCN
Higuchi John W. purchased 150,000 shares of Lipocine Inc. (LPCN) at an average of $1.50 ($1.49–$1.51, $0.23M total) across 2 trades over 2026-11-19 to 2026-11-20.
Lipocine Inc.
Lipocine is a biopharmaceutical company headquartered in Salt Lake City, Utah, focused on developing oral delivery products for drugs that are difficult to deliver by mouth. Its proprietary technology uses lipid-based formulations to improve drug absorption. The company’s portfolio includes candidates for neurological and psychiatric disorders, liver disease, and hormone supplementation for men and women. Its clinical pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, and LPCN 2203 for essential tremor. Lipocine’s commercial product is TLANDO, an oral testosterone replacement therapy approved by the FDA in March 2022. It licenses commercialization rights to partners in the United States and Canada, South Korea, the Gulf Cooperation Council countries, and Brazil, and supplies product to some licensees. It earns money through license fees, milestone payments, royalties on sales, and product supply. The company also licenses LPCN 1111, a potential once-daily oral testosterone replacement therapy candidate, in the United States and Canada.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $LPCN in the last 7 days.
Higuchi John W. purchased 150,000 shares of Lipocine Inc. (LPCN) at an average of $1.50 ($1.49–$1.51, $0.23M total) across 2 trades over 2026-11-19 to 2026-11-20.
Patel Mahesh V. (Chief Executive Officer) purchased 50,000 shares of Lipocine Inc. (LPCN) at an average of $1.59 ($1.58–$1.60) across 2 trades over 2026-11-12 to 2026-11-13.
Lipocine has dosed the first participant in its Phase 3 BLOOM study of LPCN 1154, an investigational 48-hour oral treatment for postpartum depression. The placebo-controlled study aims to enroll 120 participants, with topline results expected in the second half of 2027. The study incorporates FDA feedback and prior-trial learnings. LPCN 1154 previously failed to meet its primary endpoint in a Phase 3 trial.
Recent LPCN coverage spans financial news, regulation and insider activity.
In the last 30 days, LPCN insiders filed 4 SEC Form 4 transactions — 4 purchases ($305K) and no sales. The most active reporter was Higuchi John W. with 2 filings.
Insider open-market buying can be read as modestly bullish sentiment, but this Form 4 alone is unlikely to drive a large repricing without accompanying fundamentals.
Insider purchase signals confidence from management but the amount is modest.
First dosing in Phase 3 could lift the stock if data are positive, but uncertainty remains until results.
The start of the Phase 3 trial introduces clinical risk and upside potential, but no immediate price catalyst.
Earnings beat on a loss may prompt modest upside as the market re‑prices the surprise.
AlphAI scores every news story that mentions LPCN with an AI model for sentiment and relevance, and aggregates insider trades from Lipocine Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Higuchi John W. purchased 150,000 shares of Lipocine Inc. (LPCN) at an average of $1.50 ($1.49–$1.51, $0.23M total) across 2 trades over 2026-11-19 to 2026-11-20.
Patel Mahesh V. (Chief Executive Officer) purchased 50,000 shares of Lipocine Inc. (LPCN) at an average of $1.59 ($1.58–$1.60) across 2 trades over 2026-11-12 to 2026-11-13.
Lipocine has dosed the first participant in its Phase 3 BLOOM study of LPCN 1154, an investigational 48-hour oral treatment for postpartum depression. The placebo-controlled study aims to enroll 120 participants, with topline results expected in the second half of 2027. The study incorporates FDA feedback and prior-trial learnings. LPCN 1154 previously failed to meet its primary endpoint in a Phase 3 trial.
Lipocine Inc. (LPCN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression ● LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use in postpartum depression ● Approximately 120 participants planned for the study, which i
Lipocine (LPCN) reported Q3 EPS of -$0.08, beating estimates by $0.24, with revenue of $2.29M, exceeding expectations of $219K. The stock is down 32.39% over 3 months and 45.45% over 12 months. InvestingPro rates its financial health as 'fair performance'.
Lipocine initiated a Phase 3 study for postpartum depression treatment BRLIZIO™, expecting to enroll 120 participants. The study aims to support a potential NDA submission. The company also reported financial results for Q3 and the first nine months of 2026, showing net losses and revenue. Lipocine is exploring partnerships for BRLIZIO™ and other programs, including LPCN 2201 for MDD and LPCN 2203 for essential tremor.
Lipocine Inc (LPCN) shares rose 30% premarket after Health Canada approved its oral testosterone drug TLANDO, marketed by Verity Pharmaceuticals. TLANDO offers an alternative to injections and gels. Verity Pharma plans a 2026 Canadian launch. Over 700,000 testosterone prescriptions are written annually in Canada, with injections holding the largest share.
Lipocine Inc. (NASDAQ: LPCN) shares rose 30.95% after initiating its BLOOM Phase 3 trial for LPCN 1154, a treatment for severe postpartum depression. The company reported $1.9M in revenue and $23.3M in cash. H.C. Wainwright maintained a Neutral rating with a $4 price target, expecting data in 2027. Traders are watching for catalysts like updates or financing moves.
Lipocine announced Health Canada approval for TLANDO, an oral testosterone replacement therapy for adult males. Verity Pharma, Lipocine's licensee, plans to launch TLANDO in Canada by end-2026. The drug offers a fixed-dose option, potentially improving convenience and compliance. Over 700,000 TRT prescriptions are written annually in Canada, indicating a significant market opportunity.
Lipocine Inc. (LPCN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Lipocine Announces Health Canada Approval of TLANDO ® for Testosterone Replacement Therapy SALT LAKE CITY, October 7, 2026 -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that,